Resolvin E1, but not resolvins E2 and E3, promotes<scp>fMLF</scp>‐induced<scp>ROS</scp>generation in human neutrophils

Yuka Unno, Yoshinori Sato, Hayato Fukuda, Kohei Ishimura, Hiroyuki Ikeda, Mizuki Watanabe, Shigeru Tansho‐Nagakawa, Tsuneyuki Ubagai, Satoshi Shuto, Yasuo Ono

FEBS Letters · 2018 · 21 citations · 16 references

DOIFull text

Open access

Abstract

E-series resolvins are biosynthesized from eicosapentaenoic acid during the resolution phase of acute inflammation and enhance inflammation resolution. However, the role of E-series resolvins in inflammation resolution is not yet known. Herein, we show that in human polymorphonuclear neutrophils (PMNs), resolvin E1 (RvE1) selectively enhances reactive oxygen species (ROS) generation induced by N-formylmethionyl-leucyl-phenylalanine. The RvE1-mediated enhancement is eliminated by a pan-antagonist of leukotriene B4 (LTB4) receptors, LY255283, or an NADPH oxidase inhibitor, diphenyleneiodonium. Thus, RvE1 enhances NADPH oxidase-mediated ROS generation via LTB4 receptors. Unlike RvE1, resolvins E2 and E3 do not show such activation of PMNs. Our findings suggest that RvE1 contributes to regulation of ROS generation, in accordance with the inflammatory state of the host.

References

16